Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdulafeez Akinloye has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Advancing Host Cell Protein Characterization in Monoclonal Antibody Therapeutics: A Nanoparticle-Enriched and High-Sensitivity Mass Spectrometry Approach

    by Abdulafeez Akinloye, Sri Ramarathinam, Parul Mittal, Daniel Pincher, Leigh Donnellan, Clifford Young, Lee Xin Chong, Rhys Wyber, Mark R. Condina, Alok K. Shah, et al.

    Host cell protein (HCP) characterization in monoclonal antibody (mAb) products is challenged by a large concentration gap between low-abundance HCPs and high-abundance mAb proteins. Advances in sample preparation, chromatography, and mass spectrometry techniques have aimed at either reducing this concentration imbalance or the peptide coelution effects during chromatography. Despite this, comprehensive characterization of HCPs remains difficult, particularly at below-ppm levels, often requiring complex and low-throughput methodologies. This study presents a rapid, sensitive, and high-throughput HCP characterization workflow integrating the Seer Proteograph XT nanoparticle-enrichment platform, the Evosep ONE LC system, and timsUltra AIP mass spectrometer. This workflow enables efficient sample preparation (accommodating 40-sample digestions: 20 mAb samples within 6 h) and a 40-sample-per-day LC–MS method. Using a dynamic protein standard, the method achieved a lowest reproducible protein spike-in of 0.2 ppm, outperforming the native digestion approach (∼1 ppm). Application to NISTmAb 8671, identified over 350 HCPs, including those at sub-ppm levels, confidently and reproducibly. Furthermore, analysis of three commercial products identified 80–200 additional HCPs undetected by native digestion. Overall, our results highlight the potential of automated nanoparticle enrichment and advanced mass spectrometry for high-throughput, sensitive, and reproducible detection of low-level HCPs, enabling rapid risk assessment and improved biopharmaceutical purification strategies.

  • Middle-Down Mass Spectrometry Characterization of Monoclonal Antibody Enabled by Electron-Activated Dissociation on a Time-of-Flight Platform: A Case Study of Methionine Oxidation PTM Identification and Quantification

    by Abdulafeez Akinloye, Leigh Donnellan, Parul Mittal, Clifford Young, Mariam Nassiri, Mark R. Condina, Nathan Edwards, Alok Shah, Peter Hoffmann

    Characterizing post-translational modifications (PTMs) in monoclonal antibody products is critical for ensuring product quality attributes understanding and monitoring. While the bottom-up approach is widely adopted, it suffers from the loss of molecular connectivity and is susceptible to artifact generation. Conversely, top-down approaches face limitations due to the high complexity and poor gas-phase fragmentation of large intact molecules to get site-specific post-translational information profiling. Middle-down MS methods offer a complementary middle-ground approach to both bottom-up and top-down, with broader sequence coverage, and facilitate the simultaneous identification of multiple attributes and proteoforms. In this study, we optimized the electron-activated dissociation (EAD) approach for middle-down sequencing of NISTmAb subunits and present a potential MS and MS/MS strategy to rapidly characterize PTMs on antibodies, using methionine oxidation as an example. Peroxide-stressed and control mAb samples were digested and reduced into subunits using the IdeS enzyme and analyzed via LC-MS, with the optimized MRMHR EAD method. The resulting data enabled high-resolution subunit mass analysis, sequence confirmation, and potential for site-specific oxidation localization. Methionine oxidation localization in NISTmAb was achieved in light chain (M4), Fd’ (M34, M101), and Fc/2 (M16, M122, M192), with these locations confirmed with bottom-up peptide mapping data. Quantification using the Fc/2 subunit enabled detection of oxidation levels up to 1% relative, with strong correlation (R2 > 0.99) between expected and observed values using MS1 data. This middle-down electron-activated dissociation (EAD) approach provides a potential method for site-specific characterization of PTMs in antibody products, offering valuable complementary mapping to support formulation development and production.


  • Open Access

    Electron Activated Dissociation Technique for Middle-Down Mass Spectrometric Analysis of Disulphide Bonds and Free Thiols: Application in Characterising Monoclonal Antibody Biotherapeutic Fragments

    by Abdulafeez Akinloye, Leigh Donnellan, Clifford Young, Parul Mittal, Mark R. Condina, Peter Hoffmann

    Disulphide bonds contribute to the conformational structure of monoclonal antibodies (mAbs) and are therefore vital for their stability, biological function and safety. However, the biopharmaceutical manufacturing process can influence these bonds, potentially leading to the formation of free thiols, scrambled configurations, or degradation products, which may negatively impact quality and safety. Current analytical strategies for characterising disulphide bonds and free thiols in mAbs are predominantly based on labelled and label-free bottom-up mass spectrometry approaches. However, these methods are often time-consuming and may generate unwanted artefacts such as disulphide bond scrambled products. As a result, middle-down and top-down mass spectrometry methods are being explored as alternative approaches. However, their broader application remains limited by challenges in achieving sufficient MS/MS fragmentation for reliable characterisation of protein modifications and disulphide linkages. In this study, we evaluated an electron-activated dissociation (EAD) on the Sciex ZenoTOF 7600+ system for middle-down characterisation of intra- and interchain DSB and free thiols in mAbs. The EAD fragmentation generated diagnostic fragment ion patterns that can confirm intra-chain disulphide linkages on the subunits. This approach was applied to assess domain-specific free thiol on the NISTmAb Fc/2 subunit, as well as disulphide-scrambled products generated from mild reduction. Additionally, the method was effective in characterising fragments from antibody degradation. Overall, this EAD-based approach provides a rapid alternative for antibody product characterisation across different stages of the production process.

  • Open Access

    Electron Activated Dissociation Technique for Middle-Down Mass Spectrometric Analysis of Disulphide Bonds and Free Thiols: Application in Characterising Monoclonal Antibody Biotherapeutic Fragments

    by Abdulafeez Akinloye, Leigh Donnellan, Clifford Young, Parul Mittal, Mark R. Condina, Peter Hoffmann

    Disulphide bonds contribute to the conformational structure of monoclonal antibodies (mAbs) and are therefore vital for their stability, biological function and safety. However, the biopharmaceutical manufacturing process can influence these bonds, potentially leading to the formation of free thiols, scrambled configurations, or degradation products, which may negatively impact quality and safety. Current analytical strategies for characterising disulphide bonds and free thiols in mAbs are predominantly based on labelled and label-free bottom-up mass spectrometry approaches. However, these methods are often time-consuming and may generate unwanted artefacts such as disulphide bond scrambled products. As a result, middle-down and top-down mass spectrometry methods are being explored as alternative approaches. However, their broader application remains limited by challenges in achieving sufficient MS/MS fragmentation for reliable characterisation of protein modifications and disulphide linkages. In this study, we evaluated an electron-activated dissociation (EAD) on the Sciex ZenoTOF 7600+ system for middle-down characterisation of intra- and interchain DSB and free thiols in mAbs. The EAD fragmentation generated diagnostic fragment ion patterns that can confirm intra-chain disulphide linkages on the subunits. This approach was applied to assess domain-specific free thiol on the NISTmAb Fc/2 subunit, as well as disulphide-scrambled products generated from mild reduction. Additionally, the method was effective in characterising fragments from antibody degradation. Overall, this EAD-based approach provides a rapid alternative for antibody product characterisation across different stages of the production process.

  • Open Access

    Advancing Host Cell Protein Characterisation in Monoclonal Antibody Therapeutics: A Nanoparticle-Enriched and High-Sensitive Mass Spectrometry Approach

    by Abdulafeez Akinloye, Sri Ramaranthinam, Parul Mittal, Daniel Pincher, Leigh Donnellan, Clifford Young, Lee Xin Chong, Rhys Wyber, Mark R. Condina, Alok K. Shah, et al.

    The substantial concentration gap between low-abundance host cell proteins (HCPs) and high-abundance monoclonal antibody drug products presents a significant analytical challenge for HCP analysis using conventional proteomics workflow. Advances in sample preparation, chromatography and mass spectrometry techniques have aimed at either reducing this concentration imbalance or the peptide co-elution effects during chromatography. Despite this, comprehensive characterisation of HCPs remains difficult, particularly at below ppm levels, often requiring complex and low-throughput methodologies. In this study we report a rapid, sensitive and high-throughput approach for HCP characterisation using a workflow that integrates the Seer Proteograph XT nanoparticle-enrichment platform, the Evosep ONE liquid chromatography (LC) system, and the timsUltra AIP mass spectrometer (MS). This workflow enables efficient sample preparation (accommodating 40 samples within 6 hours) and LC-MS analysis supporting up to 40 samples per day. Using a dynamic protein standard set, the method achieved a reproducible LOD as low as 0.2 ppm, outperforming native digestion approaches, which were limited to approximately 1 ppm. Compared with previously reported methods, this workflow provided deeper HCP coverage in NISTmAb 8671, identifying over 350 HCPs, including those present at sub-ppm levels, with high confidence and reproducibility. Furthermore, application to three commercial products resulted in the identification of 80–200 additional HCPs undetected by native digestion. Overall, our results highlight the potential of automated nanoparticle-based enrichment combined with advanced mass spectrometry to enable high-throughput, sensitive characterisation of low-level HCPs in biopharmaceutical products enabling prompt risk assessment during manufacturing and next generation purification workflow development.

  • Open Access

    PKRxiv: A Best Practice Model for Advancing Pharmacoequity Through Open Pharmacokinetic Data Sharing

    by Shakir Atoyebi, Prajith Venkatasubramanian, Abdulafeez Akinloye, Oluwasegun Eniayewu, Brookie M. Best, Laura Else, Adeniyi Olagunju

    Model‐informed drug development is increasingly integrated across the drug development continuum, enabling more efficient, cost‐effective, and targeted trials while reducing reliance on animal studies. Achieving pharmacoequity requires not only equitable access to medicines but also to the data and knowledge that inform drug development and regulatory decisions. To address challenges in pharmacokinetic data sharing, PKRxiv ( https://pkrxiv.org/ ) was developed as a discipline‐specific repository designed around Findable, Accessible, Interoperable, Reusable (FAIR) principles. This tutorial introduces PKRxiv’s rationale, design, data submission and access workflows, and practical use cases. Available datasets at the end of September 2025 include over 5,500 individual drug concentration‐time data points from over 900 unique participants across 3 continents. The platform supports structured submission of pharmacokinetic, pharmacogenetic, and safety/efficacy data, with persistent digital object identifiers for discoverability and citation. Contributors can apply one of three data sharing models—unrestricted, noncommercial, or contributor‐controlled—with optional embargo periods. Users can explore datasets using the Data Explorer or Data Cards, or submit requests after providing a statement of intended use case. It enables pooling of datasets across multiple studies. Recommendations to help advance the field are proposed as data sharing becomes more widely expected: obtaining consent for unspecified future research use of data, sharing data underlying peer‐reviewed publications as standard practice, including discipline‐specific repositories in data management plans, and incentivizing post‐approval data sharing by industry. Supporting data from all therapeutic areas and population groups, PKRxiv is a critical step toward a more transparent, equitable, and collaborative future in clinical pharmacology research.


  • Open Access

    Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers

    by Abdulafeez Akinloye, Timothy Oyedeji, Oluwasegun Eniayewu, Babatunde Adeagbo, Oluseye Bolaji, Steve Rannard, Andrew Owen, Adeniyi Olagunju

    Nitazoxanide use is limited by gastrointestinal side effects associated with increasing dose. In this drug repurposing study, we investigated the possibility of enhancing the exposure of its active metabolite, tizoxanide, through pharmacokinetic interaction with atazanavir/ritonavir. In this crossover drug–drug interaction study, 18 healthy participants received a single dose of 1000 mg of nitazoxanide alone and in combination with 300/100 mg atazanavir/ritonavir in period 1 and 2 respectively. On both days, blood samples for intensive pharmacokinetic analyses were collected at 0–12 h post-dose. To explore the utility of dried blood spots (DBS) as an alternative to plasma for tizoxanide quantification, 50 µL of blood from some participants was spotted on DBS cards and correlated with plasma concentrations. Pharmacokinetic parameters were derived by non-compartmental analysis and compared between both periods. Co-administration of nitazoxanide with atazanavir/ritonavir resulted in a significant increase in tizoxanide plasma exposure [GMR (90% CI) of AUC0–12h, Cmax and C12h being 1.872 (1.870–1.875), 2.029 (1.99–2.07) and 3.14 (2.268–4.352), respectively]. DBS concentration (%CV) was 46.3% (5.6%) lower than plasma concentrations, and there was strong correlation (R = 0.95, p < 0.001) between DBS-derived plasma concentration and plasma concentrations. Co-administration with atazanavir/ritonavir enhanced tizoxanide exposure with no report of adverse events in healthy volunteers.


  • Impacts of fuel nonequidiffusivity on premixed flame propagation in channels with open ends

    by Olatunde Abidakun, Abdulafeez Adebiyi, Damir Valiev, V’yAcheslav Akkerman

    The present study scrutinizes premixed flame dynamics in micro-channels, thereby shedding light on advanced miniature micro-combustion technologies. While equidiffusive burning (when the Lewis number Le = 1) is a conventional approach adopted in numerous theoretical studies, real premixed flames are typically non-equidiffusive (Le ≠ 1), which leads to intriguing effects, such as diffusional-thermal instability. An equidiffusive computational study [V. Akkerman et al., Combust. Flame 145, 675–687 (2006)] reported regular oscillations of premixed flames spreading in channels having nonslip walls and open extremes. Here, this investigation is extended to non-equidiffusive combustion in order to systematically study the impact of the Lewis number on the flame in this geometry. The analysis is performed by means of computational simulations of the reacting flow equations with fully-compressible hydrodynamics and one-step Arrhenius chemical kinetics in channels with adiabatic and isothermal walls. In the adiabatic channels, which are the main case of study, it is found that the flames oscillate at low Lewis numbers, with the oscillation frequency decreasing with Le, while for the Le > 1 flames, a tendency to steady flame propagation is observed. The oscillation parameters also depend on the thermal expansion ratio and the channel width, although the impacts are rather quantitative than qualitative. The analysis is subsequently extended to the isothermal channels. It is shown that the role of heat losses to the walls is important and may potentially dominate over that of the Lewis number. At the same time, the impact of Le on burning in the isothermal channels is qualitatively weaker than that in the adiabatic channels.